Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Four New RNAi-Related Patent Applications Published By US Patent Office: Mar 5, 2004

Four New RNAi-Related Patent Applications Published By US Patent Office: Mar 5, 2004

Mar 05, 2004
Premium

Title: Composition and Method for Inhibiting Expression of a Target Gene. Number: 20040038921. Filed: Aug. 11, 2003. Lead Inventor: Roland Kreutzer, Ribopharma (Alnylam).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Another Cold Case Arrest

A 50-year-old cold case was cracked using genetic genealogy, the New York Times reports.

Circumventing that Pesky Poison

NPR reports that some insect pests are now becoming resistant to Bt crops.

Not Convened

Science reports the US Food and Drug Administration did not consult an outside panel in its approval of remdesivir as a COVID-19 treatment.

Nature Papers Describe Future Path for Human Genomic Research, Method to Analyze RNA Structure With Nanopore Sequencing, More

In Nature this week: a framework for future human genomic research, PORE-cupine approach to study RNA structure using nanopore sequencing, and more.

Nov
11
Featured Webinar

Leveraging Genomics to Accelerate Genetic Improvement in Aquaculture

Sponsored by
Illumina

Selective breeding represents an efficient approach to increase production of aquaculture species by means of improving traits, such as rapid growth, product quality, and disease resistance.

What's Popular?

In Gene Silencing/Gene Editing

  1. Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test With MilliporeSigma, Hamilton Company

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.